Overall, these findings confirm that CRPC heterogeneity develops as a result of survival mechanisms as a means to escape treatments, such as ARPI, either by progressing into AR-driven AdPC, AR “indifferent” CRPC-NE, or double-negative AR-null and NE marker-null PCa tumors. This evidence concerns the gene AR and posterior cortical atrophy.